文章：

探索辅助性CDK4/6抑制剂在激素受体阳性早期乳腺癌中的潜力：一种适用于所有患者的一致方法

Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All

原文发布日期：7 February 2025

DOI: 10.3390/cancers17040561

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: Hormone receptor-positive, HER2-negative breast cancer is the most common subtype, with endocrine therapy as the standard treatment. Despite the advancements in adjuvant endocrine therapy, recurrence remains a challenge, particularly in high-risk patients. Recent trials on cyclin D kinase 4/6 (CDK4/6) inhibitors in adjuvant therapy have shown promise in reducing early recurrence and improving survival. Methods: This review analyzes the clinical evidence supporting the use of CDK4/6 inhibitors, focusing on the NATALEE and monarchE trials, which demonstrate comparable efficacy and manageable safety profiles for ribociclib and abemaciclib. Results and Conclusions: Ribociclib, with its broader applicability and impact on the decision making for axillary lymph node surgery, may be the preferred option in high-risk populations. The review also addresses unanswered clinical questions and highlights the need for ongoing research to optimize the adjuvant therapy strategies.

摘要翻译： 

背景/目的：激素受体阳性、HER2阴性乳腺癌是最常见的亚型，内分泌治疗为其标准疗法。尽管辅助内分泌治疗已取得进展，但复发仍是临床挑战，尤其在高危患者中。近期关于细胞周期蛋白D激酶4/6（CDK4/6）抑制剂用于辅助治疗的临床试验显示，其在降低早期复发率和改善生存方面具有潜力。方法：本综述通过分析支持CDK4/6抑制剂应用的临床证据，重点探讨NATALEE和monarchE试验，这些研究表明瑞波西利和阿贝西利具有相当的疗效和可控的安全性。结果与结论：瑞波西利因其更广泛的适用性及对腋窝淋巴结手术决策的影响，可能成为高危人群的首选方案。本综述同时探讨了尚未解决的临床问题，并强调需要通过持续研究来优化辅助治疗策略。

原文链接：

Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All